Compare Incyte Corporation (INCY) vs Packaging Corporation of America (PKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Packaging Corporation of America — how do they compare? Incyte Corporation trades at $113.03 (market cap $22.85B), while Packaging Corporation of America trades at $229.54 (market cap $20.49B). The key difference: Incyte Corporation and Packaging Corporation of America are close in size by market cap, and Packaging Corporation of America pays a 2.61% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Packaging Corporation of America for 45 Days on average.
| INCY | PKG | |
|---|---|---|
Market Cap | $22.85B | $20.49B |
Volume | 1,927,029 | 493,499 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $257.43 |
52-Week Low | $83.80 | $191.68 |
Typical Hold Time | 33 Days | 45 Days |
Enterprise Value | $18.35B | $24.30B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Packaging Corporation of America (PKG) trades at $229.06, up 0.8% on the day, amid a bearish technical signal and mixed earnings performance. The stock shows strong profitability with a 7.26% net income margin and 14.79% ROE, though 2026 profit margins are projected to decline. Recent news highlights institutional buying and a steady dividend, while analyst consensus is a $272.43 price target with a 'Hold' bias.
PKG offers value through its dividend and stable business model but faces headwinds from cost pressures and negative cash flow trends. The stock's near-term performance hinges on Q3 2026 earnings results, with risks including margin compression and economic sensitivity. Upside exists if the company beats expectations and manages costs effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
